Importantly, this improvement did not come with a higher risk of major bleeding, a common concern with blood-thinning drugs. The findings were presented at the European Society of Cardiology Congress in Madrid and published simultaneously in The Lancet.

Why Aspirin Was the Default Choice

For many years, doctors have routinely prescribed low-dose aspirin to patients with coronary artery disease—the most common type of heart disease—to help lower the risk of blood clots. Aspirin makes blood less likely to clot, lowering the chances of blockages in narrowed arteries. This approach has been central to preventing repeat heart attacks and strokes.

Despite its popularity, aspirin has always carried a risk of gastrointestinal bleeding and, in some cases, has not been as effective as hoped over the long term.

Clopidogrel, which has been in use since the late 1990s, works differently by blocking a platelet receptor called P2Y₁₂. It has usually been given alongside aspirin as part of dual antiplatelet therapy or prescribed to patients who cannot tolerate aspirin. Until now, it was not considered a superior option for long-term use on its own.

What the Study Found

The new analysis combined data from seven clinical trials that followed nearly 29,000 patients with coronary artery disease. These patients came from different backgrounds and included those who had undergone stent placement or had experienced acute coronary syndromes.

Across this broad group, clopidogrel consistently performed better than aspirin. Patients taking clopidogrel experienced fewer major cardiovascular and cerebrovascular events, while rates of bleeding were essentially the same as those in the aspirin group.

Patients predicted to have a weaker response to clopidogrel because of genetic or clinical factors still showed better outcomes than those taking aspirin.

Evidence from Other Clinical Trials

The results align with findings from earlier studies. The HOST-EXAM trial, which followed more than 5,000 patients in South Korea after stent placement, reported fewer heart attacks, strokes, and bleeding complications in patients treated with clopidogrel instead of aspirin over almost six years.

Another trial, SMART-CHOICE 3, found that clopidogrel reduced the combined risk of death, heart attack, and stroke in high-risk patients compared to aspirin, again without raising bleeding risk. Together, these studies strengthen the case for clopidogrel as a safer and more effective long-term treatment option.

Implications for Patients and Guidelines

The latest findings indicate that clopidogrel may emerge as the favored option for long-term prevention of heart attacks and strokes in people with coronary artery disease. Experts believe the drug’s generic availability, affordability, and proven effectiveness make it suitable for widespread use. However, some considerations remain.

Clopidogrel is a prescription-only drug, unlike aspirin, which can be bought over the counter. Genetic variations in how patients metabolize clopidogrel may also influence its effectiveness in some cases, although the current analysis indicates benefits are still widespread.

Certain acid-reducing medications, such as omeprazole, may interfere with clopidogrel’s action, which means doctors will need to guide patients carefully on safe combinations.

Researchers emphasize that further studies on cost-effectiveness and outcomes in more diverse populations are needed before treatment guidelines are updated worldwide. Still, the data strongly indicate that clopidogrel provides superior long-term protection without added risks.

[Source]

The post Clopidogrel Outperforms Aspirin for Long-Term Heart Protection, Study Shows appeared first on Medical Journal Daily.

Found in Thousands of Low-Calorie Products

Erythritol appears in everything from protein bars to flavored water, offering about 80% the sweetness of sugar without the calories or spikes in insulin. Its widespread use has grown with the popularity of low-sugar and diabetic-friendly diets.

But this sweetener, often labeled as natural due to its presence in some fruits and fermentation processes, may carry hidden risks.

The new study examined how erythritol affects the blood-brain barrier—the brain’s critical filtering system. Researchers exposed brain blood vessel cells to amounts of erythritol comparable to what’s found in a single sugar-free beverage. They observed a damaging cascade: increased oxidative stress, reduced antioxidant activity, and even cell death.

These changes also disrupted the delicate balance between two key molecules: nitric oxide and endothelin-1. Nitric oxide relaxes blood vessels, promoting healthy blood flow, while endothelin-1 causes them to constrict. Erythritol lowered levels of nitric oxide while boosting endothelin-1, causing blood vessels to stay narrowed. This narrowing can limit the brain’s access to oxygen and nutrients, increasing the risk of ischaemic stroke.

It also weakened the cells’ natural capacity to break down blood clots. Normally, they release a compound called tissue plasminogen activator (t-PA) to break down clots. But erythritol suppressed this mechanism, potentially leaving clots to accumulate and increase the risk of stroke.

Echoes of Earlier Human Studies

The laboratory results align with previous human studies. One 2023 investigation that tracked over 4,000 individuals across the US and Europe found that those with elevated erythritol levels in their blood had nearly double the risk of experiencing a heart attack or stroke within three years.

Another study showed that 30 grams of erythritol—a typical serving in sugar-free ice cream—can make blood platelets more likely to clump, setting the stage for clot formation.

Erythritol is often promoted as a “natural” alternative to artificial sweeteners like aspartame or sucralose, and its chemistry makes it easier to substitute for sugar in recipes. Because it’s technically a sugar alcohol and produced in small amounts by the body, it has largely avoided the negative attention directed at other synthetic sweeteners.

However, experts warn that its natural origin does not guarantee safety. The U.S. Food and Drug Administration and European Food Safety Authority have approved it for consumption, but the new data suggest long-term effects may not be fully understood.

What This Means for Consumers

Researchers emphasize that their experiments were conducted on isolated cells in laboratory conditions. Human bodies are more complex, and more research—especially studies involving whole-body responses or advanced vascular models—is needed to draw final conclusions.

Still, scientists advise consumers to read labels and be mindful of erythritol intake, especially if they consume multiple servings of sugar-free products daily. Given the links to vascular dysfunction and stroke risk, moderation may be a wise approach.

[Source]

The post A Common Sugar Substitute May Damage Brain’s Protective Barrier, Raise Stroke Risk, New Research Warns appeared first on Medical Journal Daily.

What the Study Did

Researchers analyzed MRI scans from 557 people across the UK, Spain, and Singapore. They used data from 191 healthy individuals to build their model and tested it on 366 people who had conditions like high blood pressure, diabetes, or obesity. The focus was on two critical cardiac parameters: left atrial end-systolic volume and left atrial ejection fraction.

In healthy individuals (median age: 34), the model’s predicted heart age closely matched their real age. However, in patients with comorbidities (median age: 53), the functional heart age averaged 4.6 years older than their chronological age. For example, someone aged 50 with hypertension might have a heart functioning like that of a 55-year-old.

The ability to predict functional heart age offers a significant step forward in preventive cardiology. It reveals how underlying conditions accelerate ageing at a structural and functional level, even when outward symptoms haven’t appeared yet.

Patients with hypertension, atrial fibrillation, and diabetes mellitus had significantly older hearts than healthy controls. Functional heart age also increased with higher classes of obesity, reaching statistical significance in Class III patients.

This approach could change how clinicians manage early heart disease, potentially treating it before a patient experiences serious events like a heart attack or stroke.

Why It Matters for Public Health

Dr Pankaj Garg, who led the study and serves as a cardiologist at Norfolk and Norwich University Hospital, noted that discovering your heart is older than your actual age can motivate people to take more decisive action—such as improving blood pressure management, adopting a healthier diet, or increasing physical activity.

Knowing your heart’s functional age may also help doctors target treatment more precisely. Rather than addressing each risk factor separately, they can assess a person’s cumulative risk and intervene more effectively.

Cardiac MRI is the preferred method for assessing heart structure and performance. It also has the advantage of being radiation-free, unlike CT scans, which makes it suitable for repeated use in monitoring heart health over time.

While population-wide screening isn’t practical yet, researchers suggest that individuals already undergoing heart MRI for clinical reasons could benefit from having their scans assessed with this new model.

The model is fully automated and could be integrated into existing diagnostic systems, potentially standardizing how heart age is reported across hospitals.

The research team hopes this technique will become a valuable addition to routine cardiac assessments. It could especially help patients at high risk of cardiovascular disease make more informed decisions about their health.

The key question now, Dr Garg added, is how individuals can bring their heart’s functional age in line with their real age through better lifestyle choices and medical management.

“That means managing blood pressure, keeping glucose levels in check, staying active, and maintaining a healthy weight.”

The study, published in the Open European Heart Journal, was supported by Wellcome and conducted in collaboration with institutions in the UK, Spain, Singapore, and the Netherlands.

[Source]

The post MRI Scans Can Now Reveal Your Heart’s Functional Age appeared first on Medical Journal Daily.

Why Hot Weather Strains the Cardiovascular System

In response to intense heat, the body attempts to lower its temperature by expanding blood vessels close to the skin’s surface. While this helps with heat loss, it lowers blood pressure. To compensate, the heart has to pump faster and harder, which can stress already narrowed or damaged arteries.

At the same time, sweating causes the body to lose fluids and minerals. This makes the blood thicker and harder to pump, increasing the chances of heart strain or even heart attacks—especially in people who are dehydrated, older, or taking diuretics.

Heat can also raise inflammation and trigger changes in blood clotting. Under high temperatures, the body becomes more prone to forming clots, which can lead to blocked arteries and sudden cardiac events.

Heatwaves and Emergency Room Surges

Data from recent years show that hot days often coincide with a spike in hospital visits for heart attacks and related conditions. In fact, some studies estimate that about 2–3% of heart attack deaths in certain regions can be directly tied to extreme heat combined with air pollution.

Heatwaves lasting several days and nights significantly raise health risks. Research analyzing millions of cardiac deaths in China between 2013 and 2019 found that when both day and night temperatures stayed high, the chance of dying from a heart-related cause nearly doubled. Even single hot days raised the risk by around 16–19%.

Pollution Makes It Worse

Hot weather doesn’t just stress the heart—it also makes the air we breathe more harmful. High temperatures trap pollutants like ozone and fine particles (PM₂.₅), especially in urban areas. These tiny particles can travel deep into the lungs and bloodstream, triggering inflammation and damaging blood vessels.

When air pollution and extreme heat happen at the same time, the effects are much worse than either on their own. Days marked solely by extreme heat have been associated with a rise in overall death rates exceeding 6%. On heavily polluted days, it rose by 5%. But when both occurred together, deaths surged by over 21%.

Wildfire smoke, which is full of PM₂.₅, has also been linked to sharp increases in heart attacks during major fire seasons.

A Global Issue with Unequal Impact

Around 93,000 cardiovascular-related deaths across the globe in 2019 were attributed to elevated temperatures. The burden was not evenly distributed: South and Southeast Asia, along with parts of Africa, saw the largest numbers. Many of these areas lack robust healthcare systems and the necessary infrastructure to effectively respond to severe weather conditions.

In Australia, researchers estimate that more than 7% of the nation’s heart disease burden is already linked to heat exposure. This percentage is expected to rise significantly by 2050 if climate conditions continue on their current path.

While stroke may have the highest relative sensitivity to heat, conditions like ischemic heart disease and heart failure also show clear increases in risk during hot weather.

One city-based study in China found that extreme heat days were associated with a 56% increase in ischemic heart disease deaths, even though cold weather had an even higher relative impact. Because ischemic heart disease is so common, the overall burden from heat remains significant—especially in Asia, where such deaths have been steadily rising since 1990.

Steps to Protect High-Risk Individuals

Health agencies advise doctors and patients to take precautions during hot weather. This includes staying hydrated, limiting physical activity during the hottest parts of the day, and monitoring both temperature and air quality forecasts.

Patients with existing heart conditions should speak with their doctors about medications that may make them more vulnerable to heat, like certain blood pressure drugs or diuretics.

[Source: 1,2,3]

The post Heat Waves and Heart Attacks: How Extreme Weather Affects Cardiac Risk appeared first on Medical Journal Daily.

The Breakthrough

Lp(a) is a type of cholesterol that is inherited and increases the risk of serious heart conditions, such as heart attacks and strokes. Unlike the commonly known “bad” cholesterol (LDL), which can be controlled with diet and medication, there are currently no approved treatments to lower Lp(a).

This new drug could be a game-changer for millions of people worldwide who are at risk due to high Lp(a) levels.

The results of the Phase 2 ALPACA study, presented at the 2025 American College of Cardiology Scientific Sessions and published in the New England Journal of Medicine, showed that lepodisiran provided long-term reductions in Lp(a) levels after just one or two doses.

The drug was tested on 320 adults with elevated Lp(a) levels, who were divided into groups receiving different dosages of the drug. Those who received the highest dose (400 mg) experienced the most dramatic and long-lasting decrease in Lp(a), with levels still 74.2% lower than baseline after 1.5 years.

How Does Lepodisiran Work, and What Does It Mean for Patients?

Lepodisiran is a small interfering RNA (siRNA) therapy. This means it works by targeting the genetic instructions that tell the body to produce Lp(a), reducing its levels in the blood. Unlike daily medications, lepodisiran is administered through an injection, and its effects can last for months.

Here’s a breakdown of the key results from the trial:

Low dose (16 mg): 40.8% reduction in Lp(a)

Medium dose (96 mg): 75.2% reduction in Lp(a)

High dose (400 mg): 93.9% reduction in Lp(a)

For patients, this means that if lepodisiran proves successful in larger trials, they may have access to a treatment that significantly lowers their inherited heart disease risk with as little as one or two injections per year.

This is especially promising for individuals with a strong family history of heart disease, who often struggle to find effective prevention strategies beyond general lifestyle modifications.

Safety and Next Steps

The trial also examined the drug’s safety, and the results were encouraging. No serious side effects related to lepodisiran were reported. Some participants experienced mild reactions at the injection site, particularly at higher doses, but overall, the drug was well tolerated.

In the highest-dose group, only 14% of participants reported mild adverse effects, reinforcing the drug’s potential as a safe treatment option.

Eli Lilly has already started a Phase 3 trial, called ACCLAIM-Lp(a), which will study whether lowering Lp(a) with lepodisiran actually reduces heart attacks and strokes. If successful, this could lead to the first-ever approved treatment for high Lp(a), offering new hope to the estimated 1.4 billion people worldwide affected by this risk factor.

Researchers are optimistic that these findings could pave the way for broader applications of genetic-based therapies in cardiovascular medicine.

While more research is needed, lepodisiran represents a significant advancement in the fight against inherited heart disease. If future trials confirm its benefits, millions of people could soon have access to a long-lasting treatment that helps lower their risk of serious heart conditions.

[Source ]

The post Eli Lilly’s New Drug Shows Promise in Reducing Heart Disease Risk appeared first on Medical Journal Daily.

The development of this 3-minute heart restart system was spurred by the tragic assassination of former Japanese Prime Minister Shinzo Abe in July 2022. Abe was fatally shot during a political event, and the damage to his heart from the bullet was a key factor in his death. The incident underscored the urgent need for faster and more effective medical interventions in similar emergencies.

Associate Professor Yasuyuki Shiraishi and his team at Tohoku University’s Institute of Development, Aging, and Cancer spearheaded the project. The system they developed involves a meticulously coordinated sequence of procedures aimed at quickly resuming blood circulation. It includes securing the patient’s airway, performing an emergency thoracotomy to access the chest cavity, controlling bleeding, and administering transfusions.

A key component of the system is the use of an artificial pump. During the procedure, the left ventricle of the heart is punctured to attach this pump, which is then connected to the femoral artery to restore blood flow. In cases where connecting through the femoral artery is not feasible due to the injury’s location, alternative routes can be used. Additionally, the system can incorporate an artificial lung if the patient has sustained lung injuries.

The researchers emphasize that the critical window to prevent brain death following the cessation of blood circulation is extremely narrow—only three minutes. Traditional methods often fall short in such urgent scenarios, making this new system particularly valuable. The ability to resume circulation within this short timeframe could significantly enhance survival rates and outcomes for patients with severe injuries.

The team at Tohoku University is now focused on further developing and demonstrating the system. They believe that its implementation could lead to a substantial increase in the number of lives saved during emergencies. This advancement represents a significant step forward in emergency medical care, offering new hope for rapid and effective responses to life-threatening injuries.

References:

Japan: 3-minute heart restart system for emergencies developed by scientists.” Available from: https://www.japantimes.co.jp/news/2023/07/17/national/heart-restart-system

The post Japan: 3-Minute Heart Restart System for Emergencies Developed by Scientists appeared first on Medical Journal Daily.

Research Findings

The research, conducted by the University’s Global Academy of Agriculture and Food Systems and the University of North Carolina, Chapel Hill, utilized a simulation tool to assess the health impacts of reducing both processed and unprocessed red meat consumption. Previous studies have shown links between high processed meat intake and chronic diseases, but this study is unique in evaluating multiple health outcomes.

Methodology

Researchers created a microsimulation using data from a Centers for Disease Control and Prevention (CDC) national health survey, representing the US adult population. This simulation estimated the effects of reducing meat consumption on risks of diabetes, cardiovascular disease, colorectal cancer, and overall mortality. The impacts were analyzed across different demographics, including age, sex, household income, and ethnicity.

Significant Health Benefits

A 30% reduction in processed meat consumption could prevent 92,500 cases of cardiovascular disease and 53,300 cases of colorectal cancer over ten years. The benefits were most pronounced among white males and individuals with annual household incomes between $25,000 and $55,000.

The researchers also examined the effects of reducing both processed and unprocessed red meat. A 30% reduction in both led to a substantial decrease in disease cases, including 1,073,400 fewer diabetes cases, 382,400 fewer cardiovascular disease cases, and 84,400 fewer colorectal cancer cases. Reducing only unprocessed red meat intake by 30% could prevent over 732,000 diabetes cases, 291,500 cardiovascular disease cases, and 32,200 colorectal cancer cases.

Remaining Uncertainties

While the study highlights significant health benefits from reducing meat consumption, uncertainties remain, particularly regarding the impact of unprocessed red meat. The average daily intake of unprocessed red meat is higher than processed meat, which may explain the more substantial reduction in disease cases when unprocessed red meat consumption is reduced.

References:

1. Jaacks, L. M., Vandevijvere, S., Pan, A., et al. (2024). Health and environmental impacts of reducing processed meat consumption: A microsimulation study in the United States. The Lancet Planetary Health, Article.
2. University of Edinburgh. (2024). Cutting processed meat intake brings health benefits. News Release.

The post Cutting Processed Meat by 30% Prevents 350,000 Diabetes Cases appeared first on Medical Journal Daily.